Moderna Stock Plunges Despite ‘Vaccine Day’ Touting 31 New Shots And $21 Billion In Sales—Here’s Why One analyst blasted Moderna’s flu vaccine results as a “nonstarter” clinically, while others said investors are still too focused on Covid.